Description
Technical Information & Resources
Frequently Asked Questions
How does TrailBio® CHIR-99021 activate Wnt signaling?
By preventing GSK-3-mediated phosphorylation and subsequent proteasomal degradation of cytosolic β-catenin, TrailBio® CHIR-99021 induces rapid nuclear translocation of β-catenin. This targeted molecular switch initiates robust transcription of downstream Wnt target genes.
What concentration of TrailBio® CHIR-99021 should I use?
TrailBio® CHIR-99021 is commonly used in cell culture media at low micromolar concentrations, with effective ranges often reported between 0.1 µM and 15 µM depending on cell type, exposure duration, and experimental objective. In pluripotent stem cell workflows, concentrations around 3 µM are used in some maintenance, reprogramming, and early differentiation protocols, while higher concentrations may be applied in selected lineage-induction workflows following cell-line-specific optimization.
How does TrailBio® CHIR-99021 help guide early cell fate?
TrailBio® CHIR-99021 is commonly used to modulate Wnt signaling and help support differentiation of mesendodermal or primitive streak-like populations under defined culture conditions. Its effect depends on concentration, timing, cell density, and cell-line-specific response, so it is typically optimized as part of a broader differentiation workflow rather than used as a standalone driver of uniform cell fate.
Why does TrailBio® CHIR-99021 timing matter in differentiation?
In cardiomyocyte and nephrogenic differentiation protocols, the timing of Wnt pathway modulation is an important variable. TrailBio® CHIR-99021 is often applied early to support mesoderm or intermediate mesoderm induction, with concentration and exposure duration optimized for the specific cell line and protocol. For cardiomyocyte differentiation, early Wnt activation is commonly followed by TrailBio® CHIR-99021 withdrawal or subsequent Wnt inhibition to support later cardiac specification.
How specific is TrailBio® CHIR-99021 for GSK-3?
TrailBio® CHIR-99021 is considered a selective GSK-3α/β inhibitor and shows limited cross-reactivity with CDKs in commonly cited profiling data, although off-target activity can occur depending on concentration and assay conditions. For applications requiring precise pathway modulation, TrailBio® CHIR-99021 concentration and exposure duration should be optimized for the cell type and protocol. Higher concentrations or prolonged exposure may increase the likelihood of non-GSK-3-related effects.
Supporting Publications
Ring D.B. et al. (2003), Diabetes
- This publication describes novel substituted aminopyrimidine GSK-3 inhibitors with Ki values below 10 nmol/L and at least 500-fold selectivity over 20 other kinases.
Bennett C.N. et al. (2002), J. Biol. Chem
- This publication shows that CHIR-99021 mimics Wnt signaling in preadipocytes, stabilizes free cytosolic β-catenin, and inhibits adipogenesis by blocking induction of C/EBPα and PPARγ.
- This publication shows CHIR-99021 promotes mouse ESC self-renewal through stabilization of β-catenin and c-Myc, with β-catenin affecting nuclear signaling and E-cadherin-associated colony morphology.
